Cardiff Oncology (CRDF) Cash & Equivalents (2011 - 2026)

Cardiff Oncology has reported Cash & Equivalents for 15 years, with the latest figure at $17.5 million in Q4 2025.

• Quarterly Cash & Equivalents fell 66.06% year-over-year to $17.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $17.5 million (down 66.06% YoY) and the FY2025 annual result came in at $17.5 million, down 66.06% from the prior year.
• Cash & Equivalents grew to $17.5 million in Q4 2025 per CRDF's latest filing, from $10.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $51.5 million in Q4 2024 and troughed at $10.1 million in Q3 2025.
• A 5-year average of $18.4 million and a median of $16.9 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2021 and 2024: Cash & Equivalents sank 90.88% in 2021, then surged 137.68% in 2024.
• Over 5 years, Cash & Equivalents stood at $11.9 million in 2021, then jumped by 36.88% to $16.3 million in 2022, then soared by 32.47% to $21.7 million in 2023, then soared by 137.68% to $51.5 million in 2024, then slumped by 66.06% to $17.5 million in 2025.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $17.5 million, $10.1 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.